Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Pediatric Hematology and Oncology Program, Department of Pediatrics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Leuk Res. 2021 Dec;111:106703. doi: 10.1016/j.leukres.2021.106703. Epub 2021 Sep 14.
For patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), total body irradiation (TBI) has been particularly advocated as a part of the conditioning regimen in case of extramedullary involvement in sanctuary sites such as the central nervous system (CNS), to ensure greater tissue penetration. In resource-limited countries lacking TBI facilities; however, ALL patients undergo radiation-free myeloablative conditioning, though its impacts on post-HSCT outcomes of the patients with pre-HSCT CNS involvement have not been analyzed. In this 14-year series of 278 adult (> 18 y) ALL patients undergoing TBI-free busulfan/cyclophosphamide conditioning allo-HSCT, we found that the long-term probabilities of overall survival, disease free survival, relapse and non-relapse mortality were not significantly different between CNS-involved and CNS-spared patients. Moreover, there was no statistically significant difference in the incidence of post-HSCT CNS relapse between CNS-involved and CNS-spared patients. Pre-HSCT cranial radiation therapy (CRT) showed no significant preventive effect on the likelihood of post-HSCT CNS relapse. Through multivariable regression analysis, grade III-IV acute graft-versus-host disease (GvHD), extensive chronic GvHD and post-HSCT relapse were ascertained as independent determinants of mortality (Adj.R = 53.9 %, F = 28.1, P < 0.001), while other parameters including Philadelphia translocation, pre-HSCT CNS involvement and CRT were found to have no independent effect. Although this study was not an attempt to compare TBI-based vs. non-TBI conditioning, the TBI-free myeloablative allo-HSCT was shown to be feasible and an option for adult ALL patients with CNS involvement, considering the comparable outcomes between patients with and without CNS involvement.
对于接受异基因造血干细胞移植 (allo-HSCT) 的急性淋巴细胞白血病 (ALL) 患者,如果骨髓外有中枢神经系统 (CNS) 等避难所部位的累及,全身照射 (TBI) 一直被特别提倡作为预处理方案的一部分,以确保更大的组织穿透力。然而,在没有 TBI 设施的资源有限的国家,所有 ALL 患者均接受无放疗的清髓性预处理,但尚未分析其对伴有 HSCT 前 CNS 累及的患者 HSCT 后结局的影响。在这项针对 278 例接受无 TBI 全身 BU/CY 预处理的 allo-HSCT 的成人 (>18 岁) ALL 患者的 14 年系列研究中,我们发现伴有和不伴有 CNS 累及的患者的总生存、无病生存、复发和非复发死亡率的长期概率无显著差异。此外,伴有和不伴有 CNS 累及的患者的 HSCT 后 CNS 复发发生率无统计学差异。HSCT 前颅部放疗 (CRT) 对 HSCT 后 CNS 复发的可能性没有显著的预防作用。通过多变量回归分析,确定 3/4 级急性移植物抗宿主病 (GvHD)、广泛慢性 GvHD 和 HSCT 后复发是死亡的独立决定因素 (调整后 R = 53.9%,F = 28.1,P <0.001),而其他参数包括费城易位、HSCT 前 CNS 累及和 CRT 则没有独立影响。尽管这项研究不是为了比较基于 TBI 的与非 TBI 预处理,但鉴于伴有和不伴有 CNS 累及的患者的结局相当,无 TBI 的清髓性 allo-HSCT 对于伴有 CNS 累及的成人 ALL 患者是可行的选择。